• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Global Schizophrenia Costs Reached 243 Billion Dollars in 2019 Modelling Study

by
November 17, 2026
in Health
Reading Time: 5 mins read
0
Global Schizophrenia Costs Reached 243 Billion Dollars in 2019 Modelling Study

Global Schizophrenia Costs Reached 243 Billion Dollars in 2019 Modelling Study

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive health economic modelling analysis evaluating the global economic burden of schizophrenia across 204 countries and territories estimated that the total economic cost of the disorder reached 243.2 billion dollars in purchasing power parity in 2019 across upper-middle, lower-middle, and high-income regions. The prevalence-based cost-of-illness evaluation, focusing on adults aged 20 years and older, revealed that although schizophrenia affected an estimated 22.1 million adults globally in 2019, representing a prevalence of approximately 0.39 percent of the adult population, its individual care requirements and substantial disability generate an exceptionally large financial impact on healthcare systems, families, and broader societal economies. The multi-country investigation established that direct costs accounted for 47 percent of this total global expenditure, while indirect costs stemming from workforce productivity losses contributed 29 percent, and informal nonprofessional caregiving provided by relatives and partners accounted for 24 percent.

Schizophrenia is classified in clinical literature as a chronic and severe psychiatric disorder that ranks among the most disabling conditions across medical specialties. Core clinical manifestations include psychotic symptoms such as delusions, disorganized thinking, and hallucinations, which are frequently accompanied by prominent negative symptoms including impoverished motivation, termed avolition, and anhedonia. These negative symptoms significantly impair personal quality of life and frequently foster social withdrawal. Furthermore, individuals diagnosed with the condition experience a marked reduction in life expectancy, dying on average 15 years earlier than the general population due to factors encompassing physical medical comorbidities, accidental death, and suicide, although timely and adequate medical interventions can mitigate a portion of this excess early mortality.

Beyond individual suffering, the societal consequences of the condition are profound because affected individuals often face barriers to regular employment and community participation while requiring intensive medical treatment and continuous social support. Consequently, health economic analysts classify the associated socioeconomic burden into direct medical and nonmedical costs, indirect costs related to lost labor market productivity from premature mortality, absenteeism, and presenteeism, and informal care costs. Historically, informal caregiving has frequently been omitted from cost-of-illness studies or merged into general indirect costs. In this investigation, researchers explicitly established informal care as an independent analytical category due to its massive financial ramifications, distinct methodological measurement requirements, and separate policy implications for health systems and social support infrastructure.

To generate reliable international estimates across data-rich and data-scarce settings, the research team implemented a four-step framework building on established health economic methodologies. First, epidemiological data detailing national population counts and schizophrenia prevalence for adults aged 20 years and older, alongside working-age cohorts aged 20 to 64 years, were extracted from the Global Burden of Disease Study 2021. The selection of 2019 as the baseline index year avoided distortions in healthcare utilization and reporting caused by the global COVID-19 pandemic between 2020 and 2023. Second, the investigators performed a systematic PubMed literature search covering peer-reviewed articles published between February 2010 and April 2023, identifying primary studies documenting country-specific annual per-patient costs across direct, indirect, and informal care dimensions.

The systematic literature search yielded 657 unique articles, from which 46 studies meeting strict inclusion criteria were selected, providing 85 unique cost data points. The available empirical literature exhibited severe geographic disparities: 31 of the included studies originated from high-income regions, 13 represented upper-middle-income countries, and only two were conducted in lower-middle-income settings, with no eligible primary cost studies identified from low-income nations. To harmonize heterogeneous primary studies that reported expenditures for diverse years and currencies, all extracted per-patient figures were adjusted for inflation via the World Bank Consumer Price Index and converted into standardized 2019 purchasing power parity United States dollars using World Bank and OECD conversion factors.

To overcome extensive evidence gaps in countries lacking published economic data, the researchers implemented a stratified imputation technique adapted from health economic literature, classifying countries into four World Bank gross national income groups: low-income, lower-middle-income, upper-middle-income, and high-income. Median values for each cost type were calculated within each income tier and weighted by country-specific macroeconomic parameters. Specifically, direct and informal care cost imputations incorporated the ratio of each nation’s domestic health expenditure as a percentage of gross domestic product relative to its income group average, while indirect and informal care costs incorporated per-capita gross domestic product ratios. Imputed per-patient costs were then multiplied by national prevalence counts, and all resulting national and patient-level projections were subsequently audited and validated by a panel of four board-certified psychiatry experts to ensure clinical and methodological plausibility.

The empirical findings illustrated sharp contrasts in absolute and relative burdens across different economic tiers. High-income regions, comprising 66 countries and an adult population of 960 million, accounted for the largest aggregate expenditure at 143.6 billion dollars in purchasing power parity, with direct costs representing 46 percent and indirect and informal costs each contributing 27 percent. Upper-middle-income regions, covering 55 nations and 2.089 billion adults, incurred 77.1 billion dollars in total costs, heavily dominated by direct costs at 53 percent, alongside 31 percent indirect and 16 percent informal care costs. Lower-middle-income regions, representing 50 countries and 1.765 billion adults, accounted for 22.5 billion dollars, where expenditures were distributed relatively evenly across direct costs at 37 percent, indirect costs at 36 percent, and informal care at 27 percent.

Analysis of per-patient expenditures showed extensive international variation driven by local price structures, healthcare access, and wage levels. Annual total per-patient costs in high-income countries averaged 27,507 dollars with a median of 23,031 dollars, spanning from 8,477 dollars in the Northern Mariana Islands to 74,064 dollars in Norway. In upper-middle-income countries, annual per-patient costs averaged 10,103 dollars with a median of 9,536 dollars, ranging from 3,846 dollars in Indonesia to 25,191 dollars in Tuvalu. Lower-middle-income nations exhibited the lowest per-patient values, averaging 3,254 dollars with a median of 3,086 dollars, extending from 1,455 dollars in Palestine to 6,634 dollars in Micronesia. A supplementary exploratory regression analysis showed that gross domestic product was strongly associated with total national societal costs, whereas absolute disease prevalence exhibited a statistically significant but much smaller independent association.

When costs were evaluated as a proportion of national economic output, the geographic pattern reversed, demonstrating that upper-middle-income countries bore the heaviest relative socioeconomic burden. National schizophrenia costs accounted for an average of 0.36 percent of gross domestic product in upper-middle-income nations, reaching up to 1.40 percent in Tuvalu, compared to an average of 0.32 percent in lower-middle-income nations and 0.24 percent in high-income nations. This divergence highlights a structural mismatch in global health research, where primary health economic studies remain overwhelmingly concentrated in wealthy economies despite the heavier relative economic strain experienced by middle-income societies.

The study authors documented several important methodological limitations that contextualize these findings. Restricting literature searches to PubMed and studies published in English, German, and Spanish may have excluded relevant local health evaluations, particularly from low-resource regions. Furthermore, the complete absence of primary cost data in low-income countries prevented the model from generating reliable national cost estimates for that entire economic bracket. Additionally, the analysis excluded legal, judicial, and incarceration expenses, foregone tax revenues, and formal unemployment compensation costs, and the adult threshold of 20 years excluded early-onset adolescent cases diagnosed prior to age 18. Nevertheless, the authors concluded that these international estimates underscore the urgent necessity for policy-makers to prioritize comprehensive psychiatric management, early diagnostic interventions, evidence-based psychosocial support, and dedicated resources for informal family caregivers.

Subject of Research: Global health economic modelling of the worldwide socioeconomic burden and costs of schizophrenia

Article Title: The global cost of schizophrenia: a health economic modelling study

Article References: Welter, L. S., Montes-Martínez, M., Bohr, L., Arvandi, M., Mühlberger, N., Boon, P., Deuschl, G., Bassetti, C. L. A., Berger, T., Schulze, T. G., Vogel, D. H. V., Philipsen, A., John, M. P. L., Siebert, U., Dodel, R., Jessen, F., & Falkai, P. (2026). The global cost of schizophrenia: a health economic modelling study. International Journal of Mental Health Systems, 20(1), Article 36. https://doi.org/10.1186/s13033-026-00740-x

Image Credits: AI Generated

DOI: 10.1186/s13033-026-00740-x

Keywords: schizophrenia, health economics, cost-of-illness, direct medical costs, indirect costs, informal care costs, purchasing power parity, gross domestic product, global burden of disease, mental health economics, psychiatric disorders, economic burden, caregiver burden, productivity loss, gross national income, prevalence-based analysis, health care spending

News Source: Glenn Wilkins. (November 17, 2026). Global Schizophrenia Costs Reached 243 Billion Dollars in 2019 Modelling Study. Scienmag.

Tags: Caregiver Burdencost of illnessdirect medical costseconomic burdenGlobal Burden of Diseasegross domestic productgross national incomehealth care spendinghealth economicsindirect costsinformal care costsmental health economicsprevalence-based analysisproductivity losspsychiatric disorderspurchasing power parityschizophrenia
Share12Tweet7Share2ShareShareShare1

Related Posts

Precision Immunotherapy Targets Sepsis’s Dynamic and Biphasic Immune Response

Precision Immunotherapy Targets Sepsis’s Dynamic and Biphasic Immune Response

November 17, 2026
Forensic Linguistics Cannot Settle Disputed Suicide Cases Without Independent Corroborating Evidence

Forensic Linguistics Cannot Settle Disputed Suicide Cases Without Independent Corroborating Evidence

November 17, 2026

SFTS Case Fatality in Changqing Remained Unchanged Across Intervention Phases

November 17, 2026

Retirement In China Improves Rural Men’s Cognition But Not Urban Men’s Health

November 17, 2026

POPULAR NEWS

  • Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    29 shares
    Share 12 Tweet 7
  • Human Guided Knowledge Fusion Enhances Industrial Fault Diagnosis Graphs and Retrieval

    29 shares
    Share 12 Tweet 7
  • Geostatistical Kriging Maps Regional Ionospheric Storm Anomalies Across Türkiye

    29 shares
    Share 12 Tweet 7
  • Pediatric Mononucleosis Study Finds Exploratory Links Between Viral Load and Laboratory Measures

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Precision Immunotherapy Targets Sepsis’s Dynamic and Biphasic Immune Response

Forensic Linguistics Cannot Settle Disputed Suicide Cases Without Independent Corroborating Evidence

SFTS Case Fatality in Changqing Remained Unchanged Across Intervention Phases

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.